Total Payments
$9,361
2024 Payments
$129.33
Companies
8
Transactions
13
Medicare Patients
932
Medicare Billing
$210,499
Payment Breakdown by Category
Consulting$6,175 (66.0%)
Other$2,416 (25.8%)
Travel$537.65 (5.7%)
Research$151.32 (1.6%)
Food & Beverage$57.37 (0.6%)
Education$23.88 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,175 | 1 | 66.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,416 | 2 | 25.8% |
| Travel and Lodging | $537.65 | 2 | 5.7% |
| Unspecified | $151.32 | 3 | 1.6% |
| Food and Beverage | $57.37 | 3 | 0.6% |
| Education | $23.88 | 2 | 0.3% |
Payments by Type
General
$9,210
10 transactions
Research
$151.32
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $6,713 | 3 | $0 (2020) |
| F. Hoffmann-La Roche AG | $2,416 | 2 | $0 (2017) |
| ABBVIE INC. | $151.32 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $28.24 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $16.23 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $12.90 | 1 | $0 (2017) |
| PFIZER INC. | $11.96 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $129.33 | 2 | ABBVIE INC. ($129.33) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $6,729 | 4 | GlaxoSmithKline, LLC. ($6,713) |
| 2019 | $33.95 | 2 | AbbVie, Inc. ($21.99) |
| 2017 | $2,457 | 4 | F. Hoffmann-La Roche AG ($2,416) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $87.61 | Research |
| Study: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $41.72 | Research |
| Study: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/18/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,175.00 | General |
| 02/27/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $136.85 | General |
| 02/18/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: ONCOLOGY | ||||||
| 02/13/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $400.80 | General |
| 02/08/2019 | AbbVie, Inc. | — | — | In-kind items and services | $21.99 | Research |
| Study: M13-694 | ||||||
| 01/29/2019 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.96 | General |
| Category: ONCOLOGY | ||||||
| 10/27/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.24 | General |
| 10/12/2017 | Novartis Pharmaceuticals Corporation | INC280 (Drug), KISQALI, ZYKADIA | Food and Beverage | In-kind items and services | $12.90 | General |
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,723.00 | General |
| Category: BioOncology | ||||||
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $692.80 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ABBVIE INC. | $129.33 | 2 |
| M13-694 | AbbVie, Inc. | $21.99 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 160 | 330 | $130,083 | $25,986 |
| 2022 | 7 | 184 | 369 | $154,477 | $31,964 |
| 2021 | 9 | 316 | 732 | $255,083 | $79,355 |
| 2020 | 8 | 272 | 658 | $220,506 | $73,194 |
Total Patients
932
Total Services
2,089
Medicare Billing
$210,499
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 70 | 203 | $71,496 | $15,233 | 21.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 35 | $14,626 | $3,381 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 19 | $18,228 | $2,045 | 11.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $9,396 | $1,825 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 21 | 25 | $6,035 | $1,360 | 22.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 22 | $6,292 | $1,322 | 21.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 14 | $4,010 | $819.19 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 68 | 190 | $63,970 | $14,947 | 23.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 76 | $30,952 | $6,497 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 26 | 27 | $24,844 | $3,326 | 13.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $12,343 | $2,325 | 18.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $10,422 | $2,201 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 30 | $6,896 | $1,586 | 23.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 18 | $5,050 | $1,081 | 21.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 36 | 161 | $26,726 | $25,865 | 96.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 71 | 181 | $59,354 | $14,512 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 118 | $45,442 | $10,498 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 89 | $35,178 | $9,684 | 27.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 29 | $22,192 | $5,009 | 22.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 30 | 55 | $14,628 | $3,408 | 23.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $14,476 | $3,237 | 22.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $10,308 | $2,330 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 16 | $14,267 | $1,788 | 12.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 25 | 25 | $6,700 | $1,553 | 23.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 26 | $5,812 | $1,470 | 25.3% |
About Gini Fleming
Gini Fleming is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407918964.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gini Fleming has received a total of $9,361 in payments from pharmaceutical and medical device companies, with $129.33 received in 2024. These payments were reported across 13 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($6,175).
As a Medicare-enrolled provider, Fleming has provided services to 932 Medicare beneficiaries, totaling 2,089 services with total Medicare billing of $210,499. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/14/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1407918964
Products in Payments
- TECENTRIQ (Biological) $2,416
- KEYTRUDA (Biological) $16.23
- INC280 (Drug) $12.90
- IBRANCE (Drug) $11.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678